Is pulsed‑field ablation suitable for a patient with a severely enlarged left atrium (approximately 5–6 cm), and what are the key procedural and anticoagulation considerations?

Pulsed Field Ablation in Severely Enlarged Atria

Pulsed field ablation is suitable and safe for patients with severely enlarged left atria (5-6 cm), with evidence supporting successful outcomes even in advanced atrial substrate, though success rates may be slightly lower than in smaller atria.

Procedural Feasibility in Large Atria

PFA can effectively achieve pulmonary vein isolation and additional substrate modification in patients with severely enlarged atria. The 2025 expert consensus 1 confirms PFA's utility for pulmonary vein isolation as the primary indication, with feasibility extending to posterior wall isolation and other non-PV targets in patients with advanced substrate.

Recent data specifically addressing advanced atrial substrate 2 demonstrates that in patients with indexed left atrial volumes of 44 ± 15 mL/m² (which corresponds to significantly enlarged atria), tailored substrate-based PFA achieved:

• 100% acute procedural success
• 64% freedom from arrhythmias at 6 months
• Zero major complications
• Median procedural time of only 115 minutes

The key consideration is that while left atrial size >5.5 cm historically predicted lower success rates with thermal ablation, this should not discourage PFA candidacy. Historical surgical ablation data 3 showed that patients with LA >5.5 cm achieved 85% sinus rhythm at 2 years (vs 90% in smaller atria, P=0.35), with similar embolic stroke rates—a clinically acceptable difference.

Procedural Approach

For severely enlarged atria, adopt this structured approach:

Baseline Assessment:

• Obtain pre-procedural CT imaging for anatomical planning 4
• Measure indexed left atrial volume, not just diameter
• Assess for low-voltage areas and fibrosis burden
• Rule out left atrial thrombus with TEE or cardiac CT

Ablation Strategy:

• Perform wide-area circumferential pulmonary vein isolation as foundation 1
• Strongly consider posterior wall isolation in enlarged atria, as this substrate commonly harbors low-voltage areas and delayed electrograms 2, 5
• Posterior wall isolation with PFA is achievable in 100% of cases at first pass in 88.8% 5
• Consider mitral anterior line if anterior low-voltage areas present 2
• Use electroanatomic mapping to identify and target substrate beyond PVs

Technical Considerations:

• PFA offers tissue selectivity that reduces collateral damage risk—critical in enlarged atria where anatomical relationships may be distorted 6
• Procedure times remain reasonable (68-70 minutes skin-to-skin) even with posterior wall isolation 5
• Single transseptal puncture typically sufficient 4

Anticoagulation Management

Pre-Procedural (Critical):

• Initiate oral anticoagulation at least 3 weeks before ablation in all patients at elevated thromboembolic risk 7
• Perform uninterrupted oral anticoagulation through the procedure 7
• Mandatory intraprocedural imaging (TEE or ICE) to exclude left atrial thrombus, regardless of anticoagulation status 7

Post-Procedural (Non-Negotiable):

• Continue oral anticoagulation for minimum 2 months post-ablation in ALL patients, regardless of rhythm outcome or CHA₂DS₂-VASc score 7
• After 2 months, continue anticoagulation based on CHA₂DS₂-VASc score, NOT perceived ablation success 7
• In patients with severely enlarged atria (typically CHA₂DS₂-VASc ≥2), this means lifelong anticoagulation
• Prefer DOACs over warfarin for reduced bleeding risk 7

Key Advantages of PFA in This Population

The tissue-selective nature of PFA provides specific benefits in enlarged atria:

• No thermal injury to esophagus (critical as posterior wall proximity may be altered) 6
• Minimal phrenic nerve injury risk 6
• Shorter procedure times compared to point-by-point radiofrequency 5
• Ability to create durable posterior wall isolation without excessive collateral damage 5

Critical Caveats

Realistic Expectations:

• Arrhythmia recurrence rates are higher in severely enlarged atria (approximately 36% at 6 months in advanced substrate) 2
• Most recurrences are atrial fibrillation, but atypical flutters occur in ~11% 2
• Consider this a rhythm control strategy requiring ongoing medical management, not a cure

Durability Concerns:

• While PVI durability with PFA appears excellent, non-PV targets (mitral isthmus, coronary sinus) show poor chronic durability with only 5.5% maintaining block at 3 months 8
• This suggests that if additional linear lesions are needed, hybrid approaches or radiofrequency may be required

Contraindications:

• Active left atrial thrombus (absolute)
• Inability to maintain therapeutic anticoagulation perioperatively

Bottom line: Severely enlarged atria should not exclude patients from PFA consideration, but counsel patients that success rates are modestly lower and lifelong anticoagulation remains mandatory based on stroke risk, not ablation outcome.